- Global Pharma News & Resources

Digital PCR Market Size Like to Touch $1.05 Billion by 2027

Pune, Maharashtra, India, February 18 2021 (Wiredrelease) Allied Analytics –:Digital PCR (dPCR) is a simple and reproducible method that does not rely on a calibration curve for sample target quantification. It allows precise, highly sensitive quantification of nucleic acids. In addition, it is used for absolute quantification and analysis of minority sequences. This type of PCR enhances the sensitivity of real-time PCR and detects rare events such as single nucleotide mutations in a population of wild type sequences. With dPCR, a sample is partitioned so that individual nucleic acid molecules within the sample are localized and concentrated within many separate regions. After PCR amplification, nucleic acids may be quantified by counting the regions that contain PCR end product and positive reactions.

According to a new report published by Allied Market Research, titled, “Digital PCR Market by Technology Type, Product Type, Application, and End User: Opportunity Analysis and Industry Forecast, 2019–2027,” the global digital polymerase chain reaction market generated $398 million in 2019, and is projected to reach $1,052 million by 2027, growing at a CAGR of 12.3% from 2020 to 2027.

Click Here To Access Sample Report @

The global digital polymerase chain reaction market is expected to register substantial growth in the near future, owing to rise in prevalence of infectious diseases and increase in awareness & acceptance of personalized medicines. In addition, advancements in the technique is expected to boost the market growth during the forecast period. However, high cost of dPCR devices and reimbursement issues are the factors anticipated to hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities is expected to offer remunerative opportunities for market players.

The unprecedented nature of the COVID-19 pandemic has impacted the global economy and various businesses, which, in turn, have hampered the demand for certain products for medical and industrial applications as well as increased variability in the supply chain and manufacturing productivity. However, owing to the global pandemic, the necessity of a highly sensitive molecular diagnosis to considerably reduce false negatives reverse transcription PCR (rtPCR) results raised as a major clinical need for a robust diagnostic tool for the detection of COVID-19. Since the outbreak of the COVID-19 pandemic, significant researches have been published in supporting dPCR over quantitative polymerase chain reaction qPCR for COVID-19 testing. Furthermore, increase has been witnessed in demand for ddPCR systems and SARS-CoV-2 kits, owing to various factors such as higher sensitivity of ddPCR, lack of inhibition from sample types, and ease in understanding the results. Moreover, owing to the imperative requirement of the diagnostic tests for the COVID-19, several key players acquired the U.S. Food and Drug Administration (FDA) Emergency Use Authorization for their dPCR test kits to meet the demand. Therefore, COVID-19 had a positive impact on the global dPCR market.

For Purchase Enquiry: @

Depending on technology, the market is bifurcated into droplet digital PCR (ddPCR) and BEAMing digital PCR. The ddPCR segment was the major revenue contributor in 2019, owing to the fact that ddPCR technique provides a precise measure of DNA molecules through each drop. In addition, massive sample partitioning is a key aspect of the droplet digital PCR technique, which increases the demand.

On the basis of product type, the market is categorized into digital PCR systems, consumables & reagents, and software & services. The software & services segment is projected to exhibit the fastest growth during the forecast period, as the software helps improve the efficiency of management of digital PCR data. Thus, the demand for these products increases, thereby propelling the market growth.

North America was the leading revenue contributor to the global digital polymerase chain reaction market in 2019, and is expected to remain dominant throughout the forecast period. This is attributed to its well-developed healthcare industry, presence of leading molecular diagnostics manufacturers in the region, and rise in number of patients using personalized medicines. However, Asia-Pacific is expected to grow at the highest CAGR of 14.8% during forecast period, as it offers lucrative opportunities for molecular diagnostics players, due to increase in number of patients suffering from chronic diseases and improvement in healthcare facilities in the region.

Key Findings Of The Study 

North America occupied 47.7% share of the global digital PCR market in 2019.

The BEAMing PCR segment is anticipated to grow with the highest CAGR throughout the forecast period.

The clinical diagnostics segment accounted for 42.0% share of the global digital PCR market in 2019. 

Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 18-Feb-2021